Atopic Dermatitis Pipeline Analysis: 100+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight's, "Atopic Dermatitis Pipeline Insight, 2022" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Atopic Dermatitis Pipeline Insight Report

• DelveInsight's Atopic Dermatitis Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Atopic Dermatitis.
• The leading Atopic Dermatitis Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others are evaluating new Atopic Dermatitis drugs to improve the treatment landscape.
• Promising Atopic Dermatitis pipeline therapies such as Baricitinib, Lebrikizumab, MEDI9929, and and others are under different phases of Atopic Dermatitis clinical trials.
• The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

Get an overview of the Atopic Dermatitis Pipeline landscape, emerging therapies, clinical trials, drugs @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Overview

Atopic dermatitis often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease. Atopic dermatitis is not contagious, so it cannot be spread from person to person. Atopic dermatitis causes the skin to become extremely itchy. Scratching leads to further redness, swelling, cracking, "weeping" clear fluid, crusting, and scaling. In most cases, there are periods of time when the disease is worse, called flares, followed by periods when the skin improves or clears up entirely, called remissions. Researchers do not know what causes atopic dermatitis, but they do know that genes, the immune system, and the environment play a role in the disease.

Latest Breakthroughs of Atopic Dermatitis Treatment Landscape

• LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
• BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
• Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

Further therapy product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

DelveInsight's Atopic Dermatitis Pipeline Report covers around 100+ products under different phases of clinical development-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF Report for Atopic Dermatitis therapy pipeline assessment, treatment therapies, clinical trials @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atopic Dermatitis Pipeline Report
• Coverage- Global
• Atopic Dermatitis Pipeline Therapeutic Assessment-
o Assessment by Product Type
o Assessment by Stage and Product Type
o Assessment by Route of Administration
o Assessment by Stage and Route of Administration
o Assessment by Molecule Type
o Assessment by Stage and Molecule Type
• Atopic Dermatitis Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others
• Atopic Dermatitis Therapies- Baricitinib, Lebrikizumab, MEDI9929, and others

Dive deep into rich insights for new drugs for the Atopic Dermatitis pipeline outlook report, visit @ https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Atopic Dermatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atopic Dermatitis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Mid Stage Products (Phase II)
10. Amlitelimab: Kymab
11. Early Stage Products (Phase I/II)
12. Preclinical and Discovery Stage Products
13. Inactive Products
14. Atopic Dermatitis Key Companies
15. Atopic Dermatitis Key Products
16. Atopic Dermatitis- Unmet Needs
17. Atopic Dermatitis- Market Drivers and Barriers
18. Atopic Dermatitis- Future Perspectives and Conclusion
19. Atopic Dermatitis Analyst Views
20. Atopic Dermatitis Key Companies
21. Appendix

For further information on the Atopic Dermatitis Pipeline therapeutics assessment, reach out @ https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.